Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure

Chimeric antigen receptor (CAR) T cell therapy is one of the most promising cancer treatments. However, different hurdles are limiting its application and efficacy. In this context, how aging influences CAR-T cell outcomes is largely unknown. Here we show that CAR-T cells generated from aged female mice present a mitochondrial dysfunction derived from nicotinamide adenine dinucleotide (NAD) depletion that leads to poor stem-like properties and limited functionality in vivo. Moreover, human data analysis revealed that both age and NAD metabolism determine the responsiveness to CAR-T cell therapy. Targeting NAD pathways, we were able to recover the mitochondrial fitness and functionality of CAR-T cells derived from older adults. Altogether, our study demonstrates that aging is a limiting factor to successful CAR-T cell responses. Repairing metabolic and functional obstacles derived from age, such as NAD decline, is a promising strategy to improve current and future CAR-T cell therapies.

Authors

Institutions

Publication Details

Journal
Nature Cancer
Published
2025-05-20
DOI
https://doi.org/10.1038/s43018-025-00982-7
Citations
20
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
20.91
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure

Jesús Corría-Osorio, François Kuonen, Johan Auwerx, Massimo Andreatta et al.
20 citations
Nature Cancer
CAR-T cell therapy research
20.91
article

Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure

Jesús Corría-Osorio, François Kuonen, Johan Auwerx, Massimo Andreatta, Santiago J. Carmona, Patrizia D’Amelio, Nicola Vannini, George Coukos, Christine Pich-Bavastro, Yi-Hsuan Chiang, Ping‐Chih Ho, Jana de Sostoa, Pierpaolo Ginefra, Catherine Ronet, Helen Carrasco Hope, Denis Migliorini
article en
20 citations

Abstract

Chimeric antigen receptor (CAR) T cell therapy is one of the most promising cancer treatments. However, different hurdles are limiting its application and efficacy. In this context, how aging influences CAR-T cell outcomes is largely unknown. Here we show that CAR-T cells generated from aged female mice present a mitochondrial dysfunction derived from nicotinamide adenine dinucleotide (NAD) depletion that leads to poor stem-like properties and limited functionality in vivo. Moreover, human data analysis revealed that both age and NAD metabolism determine the responsiveness to CAR-T cell therapy. Targeting NAD pathways, we were able to recover the mitochondrial fitness and functionality of CAR-T cells derived from older adults. Altogether, our study demonstrates that aging is a limiting factor to successful CAR-T cell responses. Repairing metabolic and functional obstacles derived from age, such as NAD decline, is a promising strategy to improve current and future CAR-T cell therapies.

Nature CancerVol. 6(9)
University of Geneva (CH), Centre Hospitalier Universitaire Vaudois (CH), University Hospital of Geneva (CH), Ludwig Cancer Research (CH), Swiss Cancer Center Léman (CH), École Polytechnique Fédérale de Lausanne (CH), University of Lausanne (CH)
Good health and well-being
Openalex Percentile: Top 0%
CAR-T cell therapy research
20.91
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.